|Bid||0.00 x 1300|
|Ask||0.00 x 800|
|Day's Range||101.87 - 108.00|
|52 Week Range||51.05 - 133.74|
|Beta (3Y Monthly)||1.71|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 30, 2018 - Nov 5, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||134.60|
This upstart is developing a diagnostic test and treatment for nonalcoholic steatohepatitis, or NASH, an increasingly common liver disease.
Gilead's high-flying days are seemingly over. Intercept Pharmaceuticals, on the other hand, is only getting started.
In October, of the 17 analysts covering Intercept Pharmaceuticals (ICPT), eight have given the stock “buy” or higher ratings, and eight have given it “hold” ratings. One analyst has given Intercept a “sell.”
Nonalcoholic steatohepatitis (or NASH) focused stocks have been garnering more investor interest so far in 2018. In this series, we’ll analyze three companies with focused NASH pipelines: Intercept Pharmaceuticals (ICPT), Viking Therapeutics (VKTX), and Madrigal Pharmaceuticals (MDGL).
NEW YORK, Sept. 26, 2018 -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to.
Of the 22 analysts covering Spark Therapeutics in September, 11 of them have recommended a “buy” or higher, and nine have recommended a “hold.” Two analysts have given the stock a “sell” or lower rating. The mean rating for Spark stock is 2.41 with a target price of $69.67, implying an upside potential of 18% over its closing price of $59.04 on September 13. Its peers Esperion Therapeutics (ESPR), Intercept Pharmaceuticals (ICPT), and Axovant Sciences (AXON) have mean ratings of 2.27, 2.41, and 2.71, respectively, and target prices of $72.68, $123.07, and $4.70, respectively.
In September, there are seven analysts covering Axovant Sciences (AXON) stock. Two of them have given the stock a “buy” rating, and five have given it a “hold.” The mean rating for Axovant stock is 2.71 with a target price of $4.70, implying an upside potential of 129.3% over its trading price of $2.05 on September 11.
NEW YORK, NY / ACCESSWIRE / September 10, 2018 / Wall Street plunged on Friday after the Trump administration announced tariffs on another $267 billion worth of Chinese goods, pressuring the S&P 500 and ...
NEW YORK, Aug. 29, 2018-- Intercept Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, ...
On Friday, Fed Chairman Jerome Powell is scheduled for a speech at the Kansas City Fed’s annual summer retreat. The Nasdaq Composite Index increased 0.49 percent to close at 7,859.17. Investment strategist at Edward Jones, Kate Warne said, “I think that this is optimism on at least some partial resolution of the trade negotiations as investors are expecting progress [on that front].” “If we reach new highs that’s great but I think it would be a reflection of the positive underlying fundamentals of very positive earnings growth and modest interest rates,” Warne added.
On August 14, Array BioPharma (ARRY) announced its fourth quarter and full fiscal 2018 results for the period ended June 30, 2018. The adjusted EPS (earnings per share) for the fourth quarter came in at -$0.17, exceeding analysts’ estimate of -$0.21. Net loss in the fourth quarter of fiscal 2018 was $52.4 million as compared to $29.6 million losses reported in the fourth quarter of fiscal 2017.
Array BioPharma (ARRY) announced its fourth-quarter and full fiscal 2018 results on August 14. That day, ARRY stock registered a decline of ~2.6% and fell further the following day. The decline in stock prices was triggered by the negative investor sentiments due to the Array BioPharma’s fourth-quarter results falling short of estimates. In this article, we’ll look at analysts’ latest recommendations and target prices on ARRY stock over the next 12 months.
In June, the Committee for Medicinal Products for Human Use recommended a favorable opinion on the approval of Puma Biotechnology’s (PBYI) Nerlynx for its commercialization in the European Union for the prolonged adjuvant therapy of adults with early-stage HER2+ (hormone-receptor-positive) breast cancer whose prior adjuvant trastuzumab-based therapy is less than one year from completion.
Puma Biotechnology (PBYI) released its second-quarter earnings results on August 9. It reported net revenue of $117.3 million in the first half of 2018. Puma Biotechnology’s revenue came primarily from its sales of Nerlynx.
Heron Therapeutics and Intercept Pharmaceuticals could both produce market-crushing returns for investors over the next decade. Here's why.
On August 6, Intercept Pharmaceuticals’ (ICPT) stock price grew ~17.94% to $114.71—compared to the previous day’s closing price of $97.26. On August 6, Intercept Pharmaceuticals’ stock price closed at $114.71, which represents ~125% growth from its 52-week low of $51.05 on February 9.
NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Biotech stocks Protagonist Therapeutics and Intercept Pharmaceuticals were heading higher on Monday after positive developments and analyst upgrades. Protagonist ...
Smaller biotechs are rising, following the announcement of a collaboration between bluebird bio (BLUE) and Regeneron Pharmaceuticals to tackle cancer and a double upgrade for Intercept Pharmaceuticals (ICPT). Bluebird bio (BLUE) is soaring on news that Regeneron Pharmaceuticals said it would make a $100 million investment in the biotech's stock at $238.10 a share, which represents a 59% premium over bluebird's Friday closing price. The two companies plan to collaborate on new immune cell therapies for cancer treatment over a period of five years. Bluebird is up 4.2% to $156.26 in recent trading, while Regeneron is falling 0.6% to $392.42. In addition, Intercept Pharmaceuticals (ICPT) was on the receiving end of a double upgrade from Goldman Sachs.
Intercept (ICPT) gains on a better-than-expected second quarter as loss narrows and sales surpass estimates on a significant recovery in Ocaliva.